Notice of extraordinary general meeting | Gentian
medical, diagnostics, immunoassays, assays, in vitro diagnostics, IVD products, avian antibodies, antibodies, clinical chemistry, diagnostic tests, biotechnology
16333
post-template-default,single,single-post,postid-16333,single-format-standard,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-14.2,qode-theme-bridge,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Notice of extraordinary general meeting

Notice of extraordinary general meeting

An extraordinary general meeting of Gentian Diagnostics AS, reg. no 983 860 516 (the “Company”), will be held at the Company’s offices in:

Bjørnåsveien 5

1596 Moss

13 July 2018 at 10:00 CEST

The general meeting will be opened by the chairman of the board, Tomas Settevik, or a person authorized by him, who will make a record of attending shareholders.

The board of directors proposes the following agenda:

  1. WELCOME AND ELECTION OF A PERSON TO CHAIR THE MEETING
  2. ELECTION OF PERSON TO CO-SIGN THE MINUTES
  3. APPROVAL OF THE NOTICE AND THE AGENDA
  4. ELECTION OF BOARD MEMBER

The Company’s nomination committee proposes that Henrik Krefting is elected as a new and additional board member in the Company. Further information is included in the nomination committee’s proposal, which is made available at the Company’s website www.gentian.no.

*  *  *

Shareholders are entitled to attend the general meeting, either in person or by proxy of their own choosing, and to vote for shares

as registered in the Norwegian Central Security Depository (VPS) as of the date of the general meeting (shareholders in the Company as of 11 July 2018, as registered in the VPS on 13 July 2018). Shareholders are urged to submit a registration form per mail to Gentian Diagnostics AS, PO Box 733, 1509 Moss, or by e-mail invest@gentian.no.  Shareholders wishing to be represented and to vote by proxy at the general meeting may submit a proxy authorization to Gentian Diagnostics AS, PO Box 733, 1509 Moss, or by e-mail invest@gentian.no. Shareholders may appoint proxies with voting instructions. The proxy authorization form may also be brought to the general meeting. The registration and proxy authorization forms are enclosed with this notice as appendix 1 and 2.

Each share in the Company carries one vote at the general meeting and all shares have equal rights. At the date of this notice, the Company has 13,996,293 shares registered in the Norwegian Central Security Depository (VPS), each with a nominal value of NOK 0.10. The Company does not own any shares in the Company.

Shareholders may suggest resolutions for the items on the agenda and may ask that the board members and the general manager to provide the necessary information on matters that may affect the evaluation of the items that have been presented to the shareholders for decision, the financial position of the Company and other items up for consideration by the general meeting. This does not apply if the information required cannot be provided without disproportionate harm to the Company, cf. Section 5-15 of the Norwegian Limited Liability Companies Act.

In accordance with section 8 of the Company’s articles of association, the proposal from the nomination committee has been made available at the Company’s website www.gentian.no and, thus, is not distributed to shareholders together with the notice. However, shareholders have the right to have such documents sent to them upon request to the Company.

Questions regarding the notice, document requests or other inquires can be directed to Gentian Diagnostics AS, CFO Njaal Kind, telephone: + 47 909 16 525.

 

MeldingsID: 454903
UtstederID: GENT-ME
Instrument: GENT-ME
Marked: Merkur Market
Kategori: ANNEN INFORMASJONSPLIKTIG REGULATORISK INFORMASJON
Informasjonspliktige opplysninger: Ja
Vedlegg: Gentian Diagnostics AS – EGM notice 13 July 2018 (1)